Table 1 Patient Characteristics

# of Patients

94

46

67

Gender:

   Male

59 (63%)

30 (65%)

39 (42%)

   Female

35 (37%)

16 (35%)

28 (59%)

Age:

   ≤ 45 years

22 (23%)

10 (22%)

13 (19%)

   >45 years

72 (77%)

36 (78%)

54 (81%)

KPS:

   90-100

51 (54%)

23 (50%)

38 (57%)

   70 - 80

36 (38%)

21 (46%)

24 (36%)

   50 - 60

5 (5%)

2 (4%)

3 (4%)

   Unknown

2 (2%)

0

2 (3%)

Extent of Resection:

   GTR

75 (80%)

34 (74%)

55 (82%)

   STR

17 (18%)

10 (22%)

12 (18%)

   Biopsy

2 (2%)

2 (4%)

0

Post-operative Treatment:

   CPT-11

2 (2%)

2 (4%)

1 (1%)

   CPT-11/Celebrex

2 (2%)

2 (4%)

0

   Cyclophosphamide/Thalidomide

1 (1%)

1 (2%)

0

   Gliadel

4 (4%)

2 (4%)

2 (3%)

   Gliadel→XRT

7 (7%)

5 (11%)

7 (10%)

   Gliadel→XRT/Temo

4 (4%)

2 (4%)

2 (3%)

   Mab I¹³¹-81C6

8 (9%)

5 (11%)

7 (10%)

   Temozolomide

3 (3%)

2 (4%)

2 (3%)

   Temozolomide/CPT-11

1 (1%)

0

1 (1%)

   Temozolomide/Avastin

1 (1%)

0

1 (1%)

   Vincristine/Cisplatin/Cyclophosphamide

1 (1%)

1 (2%)

0

   XRT

19 (20%)

12 (26%)

15 (22%)

   XRT/Temo

37 (39%)

11 (24%)

26 (39%)

   None/Unknown

4 (4%)

1 (2%)

3 (4%)

Survival Status:

   Alive

7 (7%)

3 (7%)

5 (7%)

   Dead

87 (93%)

43 (93%)

62 (93%)

Available Data:

   RNA only

48 (51%)

0

48 (72%)

   IHC only

27 (29%)

27 (59%)

0

   RNA and IHC

19 (20%)

19 (41%)

19 (28%)